Detalles de la búsqueda
1.
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Gastric Cancer
; 24(4): 926-936, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33651195
2.
Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study.
Front Oncol
; 11: 695038, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34381717
3.
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Ther Adv Med Oncol
; 13: 17588359211019672, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34211587
4.
Progress and challenges in gastroesophageal cancer.
Curr Probl Cancer
; 44(6): 100590, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32451067
5.
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
PLoS One
; 15(7): e0235848, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32735623
6.
Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre.
PLoS One
; 12(9): e0184737, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28931046
7.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Eur J Cancer
; 75: 73-82, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28222309
Resultados
1 -
7
de 7
1
Próxima >
>>